BioLife Solutions Beheer
Beheer criteriumcontroles 2/4
De CEO BioLife Solutions is Rod de Greef, benoemd in Oct2023, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.47M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.68% van de aandelen van het bedrijf, ter waarde $ 7.99M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 17.5 jaar.
Belangrijke informatie
Rod de Greef
Algemeen directeur
US$10.5m
Totale compensatie
| Percentage CEO-salaris | 7.29% |
| Dienstverband CEO | 2.6yrs |
| Eigendom CEO | 0.7% |
| Management gemiddelde ambtstermijn | 2.6yrs |
| Gemiddelde ambtstermijn bestuur | 17.5yrs |
Recente managementupdates
Recent updates
BLFS: New Biopreservation Center Will Support Stronger Margins And Future Returns
Analysts have nudged their price target for BioLife Solutions higher to align with a fair value estimate of about US$32.44 per share, up from roughly US$31.30. This adjustment reflects updated assumptions around slightly lower revenue growth, a modestly higher discount rate, stronger profit margins, and a somewhat lower future P/E multiple.BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)
Summary After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses that it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing. While the shares are not cheap, revenue growth is likely at 20%+ as more client therapies become commercial. Read the full article on Seeking AlphaBioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...Expanding Cell And Gene Therapy Workflows Will Shape Future Opportunities
Market leadership in cell and gene therapy, combined with expanded high-value product offerings, drives strong revenue and margin growth opportunities.An Intrinsic Calculation For BioLife Solutions, Inc. (NASDAQ:BLFS) Suggests It's 44% Undervalued
Key Insights BioLife Solutions' estimated fair value is US$44.43 based on 2 Stage Free Cash Flow to Equity BioLife...With BioLife Solutions, Inc. (NASDAQ:BLFS) It Looks Like You'll Get What You Pay For
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales...Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 27% after a shaky period...Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
BioLife Solutions, Inc. ( NASDAQ:BLFS ), might not be a large cap stock, but it saw a significant share price rise of...Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
BioLife Solutions, Inc. ( NASDAQ:BLFS ) investors will be delighted, with the company turning in some strong numbers...Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Key Insights BioLife Solutions' estimated fair value is US$31.49 based on 2 Stage Free Cash Flow to Equity BioLife...Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
BioLife Solutions, Inc. ( NASDAQ:BLFS ), is not the largest company out there, but it led the NASDAQCM gainers with a...Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, BioLife Solutions fair value estimate is US$24.10 BioLife...Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 25% after a shaky period...Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders will have a reason to smile today, with the analysts making...Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
While BioLife Solutions, Inc. ( NASDAQ:BLFS ) might not have the largest market cap around , it received a lot of...Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$11m |
| Dec 31 2025 | US$10m | US$763k | -US$12m |
| Sep 30 2025 | n/a | n/a | -US$15m |
| Jun 30 2025 | n/a | n/a | -US$16m |
| Mar 31 2025 | n/a | n/a | -US$5m |
| Dec 31 2024 | US$7m | US$744k | -US$9m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$13m |
| Dec 31 2023 | US$6m | US$199k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$2m | US$450k | US$388k |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | US$412k | -US$9m |
| Sep 30 2021 | n/a | n/a | US$5m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$3m | US$391k | US$2m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$16m |
| Mar 31 2020 | n/a | n/a | US$39m |
| Dec 31 2019 | US$1m | US$403k | -US$2m |
Compensatie versus markt: De totale vergoeding ($USD 10.47M ) Rod } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.79M ).
Compensatie versus inkomsten: De vergoeding van Rod is gestegen terwijl het bedrijf verliesgevend is.
CEO
Rod de Greef (65 yo)
Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 2.6yrs | US$10.47m | 0.68% $ 8.0m | |
| Chief Financial Officer | 4.5yrs | US$3.27m | 0.26% $ 3.1m | |
| Chief Technology Officer | 1.5yrs | US$2.15m | 0.099% $ 1.2m | |
| Chairman of Scientific Advisory Board | 6.4yrs | US$3.19m | 0.60% $ 7.0m | |
| Chief Commercial Officer | 1.5yrs | US$1.93m | 0.25% $ 2.9m |
Ervaren management: Het managementteam van BLFS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 3.3yrs | US$10.47m | 0.68% $ 8.0m | |
| Chairman of Scientific Advisory Board | no data | US$3.19m | 0.60% $ 7.0m | |
| Member of Scientific Advisory Board | 19.6yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 18.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 19.6yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | US$284.00k | geen gegevens | |
| Member of Scientific Advisory Board | 18.7yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Lead Director | 5.1yrs | US$299.17k | 0.055% $ 644.6k | |
| Independent Director | 4.6yrs | US$254.17k | 0.11% $ 1.3m | |
| Member of Scientific Advisory Board | 17.5yrs | geen gegevens | geen gegevens | |
| Independent Director | 1.2yrs | US$234.41k | 0.028% $ 332.9k |
Ervaren bestuur: De raad van bestuur van BLFS zijn ervaren en ervaren (gemiddelde ambtstermijn van 17.5 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/20 21:06 |
| Aandelenkoers aan het einde van de dag | 2026/05/20 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
BioLife Solutions, Inc. wordt gevolgd door 18 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Robert Wasserman | Benchmark Company |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| George Zavoico | B. Riley Securities, Inc. |